Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2016

View Archived Issues

Inovio Pharmaceutical's DNA Zika virus vaccine induces robust immune responses in vivo

Corvidia Therapeutics raises Series A financing, licenses lead compound from AstraZeneca

Genedrive HCV test completes successful external assessment and gets ready for clinical testing

Beloranib achieves primary efficacy endpoint in phase IIb study in patients with severe obesity

Ironwood reports phase Ia data on soluble sGC stimulator IW-1701

Pliant Therapeutics launches with focus on fibrotic disorders

Diabetes drug pioglitazone as potential preventive therapy for recurring strokes

EZH2 inhibition exhibits in vitro and in vivo antitumor activity

Curegenix initiates phase I study of CGX-1321 in advanced solid tumors

Kasuma Partners patents PCSK9 inhibitors

Brilique 60 mg approved in E.U. for patients with history of heart attack

Bayer Schering Pharma describes ATR kinase inhibitors

Merck & Co. discloses FFAR1 agonists

Novartis reports protein kinase C inhibitors

Janssen Pharmaceutica develops mGlu2 receptor modulators

European Commission approves Zurampic for hyperuricemia in gout

Ipsen acquires rights for novel radiopharmaceuticals in oncology

FDA grants breakthrough therapy designation to PKC-412 for newly diagnosed FLT3-mutated AML

Fujifilm initiates phase I trial of FF-10502 for solid tumors, advances other cancer programs

CHLA and Thermo Fisher Scientific to develop NGS-based panel for pediatric cancer research

Temcell set to launch in Japan

Nuvo Research to split into Nuvo Pharmaceuticals and Crescita Therapeutics

FDA accepts for review sNDA for Teflaro in pediatric population

FDA grants fast track designation to Nivalis's N-91115 for cystic fibrosis

Lightlake Therapeutics changes its name to Opiant Pharmaceuticals

FDA approves Harvoni for additional chronic HCV indications

Rosetta Genomics' thyroid cancer test approved in the state of New York

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...